GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enzon Pharmaceuticals Inc (OTCPK:ENZN) » Definitions » Book Value per Share

Enzon Pharmaceuticals (Enzon Pharmaceuticals) Book Value per Share : $0.04 (As of Mar. 2024)


View and export this data going back to 1984. Start your Free Trial

What is Enzon Pharmaceuticals Book Value per Share?

Enzon Pharmaceuticals's book value per share for the quarter that ended in Mar. 2024 was $0.04.

During the past 12 months, Enzon Pharmaceuticals's average Book Value Per Share Growth Rate was 7.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Enzon Pharmaceuticals was 146.90% per year. The lowest was -72.40% per year. And the median was -6.10% per year.

Enzon Pharmaceuticals's current price is $0.23. Its book value per share for the quarter that ended in Mar. 2024 was $0.04. Hence, today's PB Ratio of Enzon Pharmaceuticals is 5.23.

During the past 13 years, the highest P/B Ratio of Enzon Pharmaceuticals was 10.59. The lowest was 0.68. And the median was 1.60.


Enzon Pharmaceuticals Book Value per Share Historical Data

The historical data trend for Enzon Pharmaceuticals's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzon Pharmaceuticals Book Value per Share Chart

Enzon Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.14 -0.45 0.07 0.05 0.05

Enzon Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.04 0.03 0.05 0.04

Competitive Comparison of Enzon Pharmaceuticals's Book Value per Share

For the Biotechnology subindustry, Enzon Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enzon Pharmaceuticals's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enzon Pharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where Enzon Pharmaceuticals's PB Ratio falls into.



Enzon Pharmaceuticals Book Value per Share Calculation

Enzon Pharmaceuticals's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(3.51-0.00)/74.21
=0.05

Enzon Pharmaceuticals's Book Value Per Share for the quarter that ended in Mar. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(3.29-0.00)/74.21
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Enzon Pharmaceuticals  (OTCPK:ENZN) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Enzon Pharmaceuticals Book Value per Share Related Terms

Thank you for viewing the detailed overview of Enzon Pharmaceuticals's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Enzon Pharmaceuticals (Enzon Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
20 Commerce Drive, Suite 135, Cranford, NJ, USA, 07016
Enzon Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the provision of licensing arrangements related to sales of drug products that utilize its proprietary technology. The company earns revenue in the form of royalties. Primary source of royalty revenues derived from the sales of PegIntron, which is marketed by Merck.
Executives
Randolph C Read director C/O NEW YORK REIT, INC., 405 PARK AVENUE, NEW YORK NY 10022
Jaffrey Adam Firestone director C/O CVR ENERGY, INC., 2277 PLAZA DRIVE, SUITE 500, SUGAR LAND TX 77479
Family Fund Couchman other: See Footnote 1 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Jordan Bleznick director C/O ENZON PHANNACEUTICALS, INC., 120 COMMERCE DRIVE (SUITE 135), CRANFORD NJ 07016
Pearce Michael Cooper other: See explanation of responses 213 RHODODENDRON DRIVE, CHAPEL HILL NC 27517
Harper Asset Management Llc other: See explanation of responses 2945 S CENTER GREEN CT, G215, BOULDER CO 80301
Brian James Harper other: See explanation of responses 6680 GUNPARK DRIVE, SUITE 202B, BOULDER CO 80301
Myrexis, Inc. other: See Footnote 1 600 FIFTH AVENUE, 2ND FLOOR, NEW YORK NY 10020
Xstelos Corp. other: See Footnote 1 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Jonathan Couchman 10 percent owner, other: See Footnote 1 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Carl C Icahn 10 percent owner C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH-1, SUNNY ISLES BEACH FL 33160
Richard L Feinstein officer: VP-Finance and PFO
Jonathan Christodoro director C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH, SUNNY ISLES FL 33160
Kostas D Odysseas director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Jennifer Isacoff Mcnealey director C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO Z4 92121

Enzon Pharmaceuticals (Enzon Pharmaceuticals) Headlines

From GuruFocus

Top Micro-Cap Picks From the Gurus

By Sheila Dang Sheila Dang 06-23-2015

Enzon Inc. Reports Operating Results (10-K)

By gurufocus 10qk 03-16-2011

Icahn Files 13D on Enzon Pharma

By gurufocus Todd Sullivan 03-14-2008

Enzon Pharmaceuticals Announces Key Dates for Rights Offering

By Marketwired Marketwired 09-16-2020

Enzon Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 05-10-2010

Enzon Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 11-04-2009